No quarterly revenue total was found in Telomir Pharmaceuticals, Inc.'s SEC filings.
Telomir Pharmaceuticals, Inc. (TELO) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-1.72M
+66.0% vs year-ago quarter
Operating cash flow
$-1.01M
-45.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.79
-364.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
68.77M
+113.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TELO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971532
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$1.7M | -$990,947 | -$2.1M | -$1.1M | -$5.1M |
| Diluted EPS | -$0.79 | -$0.03 | -$0.06 | -$0.03 | -$0.17 |
| Operating cash flow | -$1.0M | -$1.8M | -$1.2M | -$927,264 | -$696,445 |
| Total assets | $5.4M | $5.8M | $7.3M | $7.4M | $829,611 |
| Total liabilities | $332,424 | $827,310 | $1.4M | $422,807 | $348,388 |
| Stockholders' equity | $5.0M | $5.0M | $5.9M | $7.0M | $481,223 |
| Cash and investments | $5.2M | $5.6M | $7.3M | $7.3M | $800,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 6, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 16, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
All 147 Telomir Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.